Clinical Trials
23 trialsNCT04567420 2026-06-03
DARE
Criterium, Inc.
Phase 2 Recruiting
NCT07023289 2026-06-02
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
Phase 2 Recruiting
NCT04844866 2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT04485949 2026-02-10
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
Phase 2 Active not recruiting
NCT05608044 2025-09-04
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Agenus Inc.
Phase 2 Active not recruiting
NCT06636682 2024-10-21
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics Inc
Phase 2 Recruiting
NCT04099888 2023-09-11
RELEASE
PCI Biotech AS
Phase 2 Terminated
NCT04733833 2023-02-01
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 2 Completed
NCT02107937 2022-05-04
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT02448810 2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
Phase 2 Terminated
NCT03301597 2021-03-30
LAUNCH
Nohla Therapeutics, Inc.
Phase 2 Terminated
NCT01883362 2021-03-17
RADIUS
Novartis
Phase 2 Completed
NCT04450160 2020-06-29
AEO
MetVital, Inc.
Phase 2 Unknown
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT03472053 2020-05-19
A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
BioMarck Pharmaceuticals, Ltd.
Phase 2 Completed
NCT02200081 2018-11-15
IMPULSE
Mologen AG
Phase 2 Completed
NCT02107950 2018-08-15
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT01353222 2017-05-25
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
Phase 2 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT00977379 2016-11-15
XERAD
Hoffmann-La Roche
Phase 2 Terminated
NCT01360840 2015-12-14
PERSEUS
EMD Serono
Phase 2 Completed
NCT00459641 2012-07-17
Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts
Kuros Biosurgery AG
Phase 2 Withdrawn